A detailed history of Tower Research Capital LLC (Trc) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,697 shares of VRDN stock, worth $70,353. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,697
Previous 9,794 62.25%
Holding current value
$70,353
Previous $127,000 33.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $74,139 - $142,243
-6,097 Reduced 62.25%
3,697 $84,000
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.26 $100,896 - $150,127
8,698 Added 793.61%
9,794 $127,000
Q1 2024

May 15, 2024

SELL
$17.09 - $23.82 $21,106 - $29,417
-1,235 Reduced 52.98%
1,096 $19,000
Q4 2023

Feb 13, 2024

SELL
$11.12 - $22.5 $75,849 - $153,472
-6,821 Reduced 74.53%
2,331 $50,000
Q3 2023

Nov 14, 2023

BUY
$15.16 - $24.7 $63,656 - $103,715
4,199 Added 84.78%
9,152 $140,000
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $39,158 - $51,477
1,735 Added 53.92%
4,953 $117,000
Q1 2023

May 09, 2023

BUY
$25.04 - $37.6 $76,497 - $114,868
3,055 Added 1874.23%
3,218 $82,000
Q4 2022

Feb 10, 2023

SELL
$18.78 - $29.74 $150,427 - $238,217
-8,010 Reduced 98.01%
163 $5,000
Q3 2022

Nov 10, 2022

BUY
$10.7 - $25.5 $57,191 - $136,297
5,345 Added 189.0%
8,173 $167,000
Q2 2022

Aug 15, 2022

BUY
$9.55 - $19.0 $3,342 - $6,650
350 Added 14.12%
2,828 $33,000
Q1 2022

May 12, 2022

BUY
$16.79 - $20.88 $41,588 - $51,719
2,477 Added 247700.0%
2,478 $45,000
Q4 2021

Feb 14, 2022

BUY
$15.65 - $21.5 $15 - $21
1 New
1 $0
Q2 2021

Aug 16, 2021

SELL
$14.34 - $18.67 $1,692 - $2,203
-118 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$15.5 - $24.93 $1,829 - $2,941
118 New
118 $2,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $759M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.